Scarica l'app Stockscreener
1.70
11.84%
0.18
Precedente Chiudi:
$1.52
Aprire:
$1.53
Volume 24 ore:
125.39K
Relative Volume:
0.27
Capitalizzazione di mercato:
$5.66M
Reddito:
$35.75M
Utile/perdita netta:
$11.57M
Rapporto P/E:
-0.4466
EPS:
-3.8069
Flusso di cassa netto:
$-26.25M
1 W Prestazione:
+12.58%
1M Prestazione:
+25.00%
6M Prestazione:
-43.52%
1 anno Prestazione:
-83.56%
Intervallo 1D:
$1.51
$1.7099
Intervallo di 1 settimana:
$1.47
$1.7099
Portata 52W:
$1.06
$11.07
Redhill Biopharma Ltd Adr Stock (RDHL) Company Profile
Confronta RDHL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RDHL
Redhill Biopharma Ltd Adr
|
1.70 | 5.06M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
ZTS
Zoetis Inc
|
146.93 | 65.35B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.09 | 47.75B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.40 | 41.52B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.38 | 21.43B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
403.68 | 18.00B | 2.99B | 1.21B | 1.13B | 25.06 |
Redhill Biopharma Ltd Adr Stock (RDHL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-08-31 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-05-18 | Iniziato | H.C. Wainwright | Buy |
| 2020-09-11 | Iniziato | BTIG Research | Buy |
| 2019-07-12 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2019-03-12 | Aggiornamento | WBB Securities | Speculative Buy → Buy |
| 2018-01-26 | Iniziato | Nomura | Buy |
| 2017-10-06 | Iniziato | Seaport Global Securities | Buy |
| 2017-10-04 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-24 | Reiterato | FBR & Co. | Outperform |
| 2016-07-27 | Reiterato | FBR Capital | Outperform |
| 2015-09-29 | Iniziato | Nomura | Buy |
| 2015-07-29 | Reiterato | ROTH Capital | Buy |
| 2015-06-17 | Reiterato | H.C. Wainwright | Buy |
| 2015-06-15 | Reiterato | ROTH Capital | Buy |
Mostra tutto
Redhill Biopharma Ltd Adr Borsa (RDHL) Ultime notizie
RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights - Placera.se
RedHill Biopharma receives Nasdaq extension to regain compliance by October - Investing.com South Africa
Redhill Biopharma stock soars after FDA provides positive pathway for Crohn’s drug - Investing.com India
Taking the lead: Redhill Biopharma Ltd. ADR (RDHL) - Sete News
The time has not yet come to remove your chips from the table: Hertz Global Holdings Inc (HTZ) - Sete News
A significant driver of top-line growth: Alexandria Real Estate Equities Inc (ARE) - Sete News
Redhill Biopharma Ltd. ADR [RDHL] Insider Activity: An Update for Investors - knoxdaily.com
RedHill Biopharma faces Nasdaq non-compliance issue - Investing.com
RedHill Biopharma faces Nasdaq non-compliance issue By Investing.com - Investing.com India
Redhill Biopharma stock hits 52-week low at $1.72 amid market challenges - Investing.com
Redhill Biopharma stock hits 52-week low at $2.47 amid steep annual decline - Investing.com
RedHill Biopharma targets UK approval for H. pylori therapy By Investing.com - Investing.com South Africa
RedHill Biopharma targets UK approval for H. pylori therapy - Investing.com
Redhill Biopharma Ltd. ADR (RDHL)’s Stock Price Falls Due To Weak Fundamental Momentum - Marketing Sentinel
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline - Investing.com
Hyloris secures global rights to RedHill's RHB-102 - Investing.com
Redhill Biopharma stock hits 52-week low at $4.79 - Investing.com
RedHill tests opaganib with Bayer's drug in prostate cancer study - Investing.com
RedHill stock rises on expanded Medicare coverage By Investing.com - Investing.com South Africa
RedHill Biopharma Announces Plan to Implement ADS Ratio Change - PR Newswire
RedHill Biopharma finalizes agreement to enhance cash position - Investing.com
Balancing Acidity: Exploring the Proton Pump Inhibitors Market - openPR.com
symbol__ Stock Quote Price and Forecast - CNN
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S. - Barchart.com
RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds - Barchart.com
RedHill Biopharma to Implement ADS Ratio Change to 1:400 By Investing.com - Investing.com India
Why Beyond Meat Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket - Benzinga
Extremely Robust COVID-19 Clinical Trial Pipeline With 420+ Key Companies Expected to Change the Pace of the COVID-19 Treatment - PR Newswire UK
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D - PR Newswire
RedHill Biopharma to Focus Commercial Efforts on Talicia® - GlobeNewswire
RedHill Biopharma: TALICIA Launch For H. Pylori In Sight - Investing.com
RedHill Biopharma's Drug Pipeline May Merit Substantial Upside, And Potential Catalysts Are On The Horizon - Seeking Alpha
S&W Seed Company (SANW): How Does It Stack Up Against Its Peers? - Insider Monkey
RedHill Biopharma files for further Nasdaq offering - גלובס
Redhill Biopharma (RDHL) Stock Price, News & Analysis - MarketBeat
Redhill Biopharma Ltd Adr Azioni (RDHL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.75%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):